• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Mackenzie's Mission HomepageMackenzie's Mission

DONATE Mackenzies Mission Donate
  • Mission
  • About
    • The Story
    • Board
  • Resources
    • Resource List
    • What Is Amyloidosis
  • Speakers Bureau
    • About ASB
    • ASB Operating Committee
  • Fundraisers
  • Blog
  • Contact

attrv

Hereditary Amyloidosis: The T60A Variant

February 23, 2023

Hereditary transthyretin amyloidosis is caused by a genetic mutation which causes misfolding of transthyretin (TTR) proteins (which originate from the liver). There are over 100 genetic variants of hereditary amyloidosis. One such variant, called T60A, is the most common variant in Ireland (and the UK).

Filed Under: Featured News Tagged With: amyloidosis, ATTR amyloidosis, attrv, hATTR, Hereditary Amyloidosis, Irish Variant, T60A

Worldwide Hotspots of Hereditary ATTR Amyloidosis (ATTRv)

January 26, 2023

Transthyretin Amyloidosis, or ATTR, is considered a single disease, however the diversity in its clinical presentation is staggering. In this blog, we’ll discuss some of the most common hereditary variants and how the disease manifestation differs around the world in documented hotspots.

Filed Under: Featured News, What Is Amyloidosis Tagged With: amyloidosis, amyloidosis variants, ATTR amyloidosis, attrv, global amyloidosis, hATTR, Hereditary Amyloidosis, worldwide amyloidosis

ATTR-CM (cardiomyopathy) vs ATTR-PN (peripheral neuropathy)

June 23, 2022

Over the course of the past two months, we spent time discussing two of the most common hallmark symptoms of ATTR amyloidosis: cardiomyopathy and peripheral neuropathy. In this article, we’ll briefly recap both hallmark symptoms as well as bring it all together by discussing the two most common forms of ATTR amyloidosis: ATTR cardiomyopathy (ATTR-CM) and ATTR peripheral neuropathy (ATTR-PN).

Filed Under: Featured News, What Is Amyloidosis Tagged With: amyloidosis, amyloidosis diagnosis, ATTR amyloidosis, ATTR-CM, ATTR-PN, attrv, ATTRwt, cardiomyopathy, hATTR, neuropathy, polyneuropathy

FDA Approved AMVUTTRA for hATTR

June 14, 2022

Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Filed Under: Featured News, What Is Amyloidosis Tagged With: amyloidosis, amyloidosis treatment, ATTR amyloidosis, attrv, FDA Approved, hATTR, Hereditary Amyloidosis

Peripheral Neuropathy & Amyloidosis

May 26, 2022

Neuropathy, also known as peripheral neuropathy, is a broad term that is used to describe damage to the nerves outside of the brain and spinal cord. There are over 100 types of peripheral neuropathy that can be classified into four categories, with each type having their own symptoms and prognosis. In this article, we’ll discuss the types of peripheral neuropathy and its connection to amyloidosis.

Filed Under: Featured News, What Is Amyloidosis Tagged With: AL amyloidosis, amyloidosis, amyloidosis diagnosis, ATTR amyloidosis, attrv, ATTRwt, diagnosing amyloidosis, hATTR, Hereditary Amyloidosis, light chain amyloidosis, wild-type amyloidosis

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

Recent News

  • FACES of Amyloidosis 2023
  • Hereditary Amyloidosis: The T60A Variant
  • Worldwide Hotspots of Hereditary ATTR Amyloidosis (ATTRv)
  • 2022: Mackenzie’s Mission – Our Report Card
  • CRISPR/Cas9 – ATTR Clinical Trial Update

Be A Part Of Our Mission!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

  • Mission
  • About
  • Resources
  • Speakers Bureau
  • Fundraisers
  • Blog
  • Contact

Registered 501(c)(3) · Contact · Copyright © 2023 · Mackenzies Mission - All Rights Reserved